Rep. Val T. Hoyle Sells Off Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• Representative Val T. Hoyle sold shares of BioNTech SE (NASDAQ:BNTX) for between $1,001 and $15,000 on August 7th, disclosed in a filing on September 12th.
• BioNTech recently reported a loss of $1.60 earnings per share for the quarter, missing analyst estimates, despite a significant year-over-year revenue increase of 102.6%.
• Analysts have given BioNTech a consensus rating of "Moderate Buy" with price targets ranging between $112.00 and $155.00, indicating a positive outlook for the stock.

Representative Val T. Hoyle (D-Oregon) recently sold shares of BioNTech SE Sponsored ADR NASDAQ: BNTX. In a filing disclosed on September 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BioNTech stock on August 7th. The trade occurred in the Representative's "FIDELITY ROLLOVER IRA" account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Walgreens Boots Alliance NASDAQ: WBA on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Palo Alto Networks NASDAQ: PANW on 8/19/2025.
• Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of Uber Technologies NYSE: UBER on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Johnson Controls International NYSE: JCI on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Copart NASDAQ: CPRT on 8/19/2025.
• Purchased $1,001 - $15,000 in shares of Tyler Technologies NYSE: TYL on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of United Rentals NYSE: URI on 8/7/2025.

BioNTech Stock Down 0.1%

BNTX stock traded down $0.09 during midday trading on Friday, hitting $96.22. The stock had a trading volume of 2,158,031 shares, compared to its average volume of 1,235,562. The firm has a market cap of $23.13 billion, a price-to-earnings ratio of -60.14 and a beta of 1.39. The business has a 50-day moving average of $107.34 and a two-hundred day moving average of $103.51. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. During the same period in the previous year, the company earned ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Banque Cantonale Vaudoise bought a new position in BioNTech in the first quarter valued at about $36,000. LRI Investments LLC lifted its holdings in BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after acquiring an additional 312 shares during the period. Tower Research Capital LLC TRC lifted its holdings in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after acquiring an additional 305 shares during the period. Hantz Financial Services Inc. lifted its holdings in BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock valued at $61,000 after acquiring an additional 472 shares during the period. Finally, Banque Transatlantique SA bought a new position in BioNTech in the first quarter valued at about $80,000. 15.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Morgan Stanley upped their price target on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. HC Wainwright reissued a "buy" rating and issued a $136.00 target price on shares of BioNTech in a research note on Monday, September 8th. Truist Financial reissued a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Leerink Partners set a $112.00 target price on BioNTech in a research note on Monday, June 2nd. Finally, Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an "overweight" rating in a research note on Tuesday, August 5th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $134.23.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon's 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon's 4th Congressional District. She declared candidacy for the 2026 election. Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.